Insider Selling: CVS Caremark CFO Sells 74,989 Shares of Stock (CVS)
CVS Caremark (NYSE:CVS) CFO David M. Denton sold 74,989 shares of the company’s stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $75.88, for a total transaction of $5,690,165.32. Following the transaction, the chief financial officer now directly owns 181,662 shares of the company’s stock, valued at approximately $13,784,513. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
CVS has been the subject of a number of recent research reports. Analysts at Susquehanna raised their price target on shares of CVS Caremark from $85.00 to $90.00 in a research note on Friday, June 6th. They now have a “positive” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of CVS Caremark in a research note on Thursday, May 29th. They now have a $81.00 price target on the stock. Finally, analysts at Deutsche Bank raised their price target on shares of CVS Caremark from $80.00 to $83.00 in a research note on Wednesday, May 28th. One research analyst has rated the stock with a sell rating, six have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. CVS Caremark presently has an average rating of “Buy” and a consensus target price of $77.21.
Shares of CVS Caremark (NYSE:CVS) traded up 0.76% during mid-day trading on Thursday, hitting $76.83. The stock had a trading volume of 2,040,838 shares. CVS Caremark has a 52 week low of $56.32 and a 52 week high of $79.43. The stock has a 50-day moving average of $76.82 and a 200-day moving average of $72.95. The company has a market cap of $90.122 billion and a price-to-earnings ratio of 19.42.
CVS Caremark (NYSE:CVS) last announced its earnings results on Friday, May 2nd. The company reported $1.02 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.05 by $0.03. The company had revenue of $32.70 billion for the quarter, compared to the consensus estimate of $32.31 billion. During the same quarter in the prior year, the company posted $0.22 earnings per share. The company’s quarterly revenue was up 6.3% on a year-over-year basis. Analysts expect that CVS Caremark will post $4.46 EPS for the current fiscal year.
CVS Caremark Corporation (NYSE:CVS), together with its subsidiaries, is a pharmacy health care provider in the United States.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.